Switch version of Marvel’s Midnight Suns cancelled as the game is dated for Xbox One and PS4
The title is coming to last-gen consoles next week alongside its final post-launch DLC
2K Games has cancelled plans to release Marvel’s Midnight Suns for Nintendo Switch.
The news was announced on Tuesday alongside a release date for the delayed Xbox One and PS4 versions of the Firaxis-developed game.
The last-gen console versions will be released digitally on May 11, with no plans for a physical release.
“The Nintendo Switch version of Marvel’s Midnight Suns will no longer be offered as part of updated plans,” 2K said in a press release.
Marvel’s Midnight Suns’ fourth and final post-launch DLC, Blood Storm, will also launch on May 11.
Available for either standalone purchase or as part of the game’s Season Pass, each DLC pack introduces a new recruitable hero (Deadpool, Venom, Morbius, Storm) and three new story missions.
Following a delay from the game’s previously planned October launch window, the PS5, Xbox Series X/S and PC versions of Midnight Suns were released in early December.
While the game was well-received critically, all versions were heavily discounted within a month of release, suggesting that its publisher had been disappointed with its commercial performance.
This was seemingly confirmed in February, with Bloomberg’s Jason Schreier reporting that the game had flopped at retail.
Take-Two boss Zelnick told the publication “it’s possible the release window wasn’t perfect” but that he believed Midnight Suns could sell well in the long-term, like other Firaxis titles.
It was announced in February that Jake Solomon, the director of Midnight Suns and the XCOM franchise, was leaving Firaxis after more than two decades as part of a major studio shake-up.
2K also confirmed that studio head Steve Martin was leaving Firaxis after 25 years and being replaced by former chief operating officer Heather Hazen.
At the same time, it announced that the next mainline game in the Sid Meier’s Civilization series is in development at the studio.